Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 44

Results For "marketing"

818 News Found

CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests
Clinical Trials | August 16, 2023

CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests

CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions


DKSH and Biolin Scientific extend partnership in the APAC region
News | August 09, 2023

DKSH and Biolin Scientific extend partnership in the APAC region

DKSH has further fortified its strategic partnership with Biolin Scientific, a globally recognized pioneer in surface science instrumentation, across nine key markets in the APAC region


USFDA completes PAD E inspection of Marksans' Goa facility
Drug Approval | August 09, 2023

USFDA completes PAD E inspection of Marksans' Goa facility

The inspection was conducted at its Goa, Vema manufacturing facility


USFDA approves Merck’s ERVEBO for use in children 12 months of age and older
Drug Approval | August 05, 2023

USFDA approves Merck’s ERVEBO for use in children 12 months of age and older

Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease


Yashoda Medicity, Indirapuram and Draeger India join hands to establish modular ICU setup
Healthcare | August 05, 2023

Yashoda Medicity, Indirapuram and Draeger India join hands to establish modular ICU setup

Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes


Supriya Lifescience collaborates with Plasma Nutrition for protein technology
News | August 03, 2023

Supriya Lifescience collaborates with Plasma Nutrition for protein technology

The primary purpose of this collaboration is to bring the optimized protein into the Indian market


Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Drug Approval | August 01, 2023

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy


NATCO files generic Erdafitinib Tablets in USA
Drug Approval | July 26, 2023

NATCO files generic Erdafitinib Tablets in USA

Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma